Oprozomib

Drug Profile

Oprozomib

Alternative Names: ONO-7058; ONX-012; ONX-0912; OPZ; PR-047

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Onyx Pharmaceuticals
  • Class Amides; Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules; Thiazoles
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I/II Haematological malignancies; Multiple myeloma
  • Phase I Solid tumours

Most Recent Events

  • 18 Oct 2016 Amgen plans the phase Ib OPomD trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT029391830)
  • 21 Sep 2015 Phase-I/II development is ongoing for Haematological malignancies in USA
  • 28 Oct 2014 Oprozomib receives Orphan Drug status for Multiple myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top